For alle kontrollerede studier var seponeringsraten på grund af bivirkninger 12, 2% for patienter randomiseret til lacosamid, og 1, 6% for patienter randomiseret til placebo.
Over all controlled studies, the discontinuation rate due to adverse reactions was 12.2% for patients randomized to lacosamide and 1.6% for patients randomized to placebo.